This lens implant, used for "free" patients, costs INR 285, equivalent to less than $5 USD |
The elegance of the Aravind mission, is that they can offer
surgery for “free”, to cure blindness from cataract. Each “free surgery” incurs an expense of
INR 750 (which as of
this writing is $12.25 USD). This cost is absorbed by Aravind, while at the same time offering a value proposition
to the “paying” patients, whose payments offset the expenses of the Aravind
mission. To control the cost of surgery,
and to perform surgery efficiently, MSICS is the ideal procedure. MSICS was born, after a 1990 article detailed
proper wound and tunnel construction for sutureless self-sealing incision. In fact, MSICS is a “newer” surgery than
phacoemulsification. It was developed to
be safer and faster than ECCE, less expensive than ECCE and
phacoemulsification, and easier to deploy in developing countries. MSICS combine surgical features of both
techniques. Like ECCE, the cataract is
delivered totally in one piece, and the surgical instruments are reusable and
can be sterilized. Unlike ECCE, the
wound is self-sealing, does not require suturing, and has much less risk than
ECCE. There is no added cost of sutures
to close the wound as in ECCE, and there is no capital outlay for a
phacoemulsification device as phaco surgery.
There are no disposable phaco cartridge or tubing, no disposable phaco
or I/A tip, that would otherwise drive up the cost of surgery. To further keep the cost low, the surgeons at
Aravind use HPMC gel (hydroxypropyl methylcellulose) to maintain the anterior
chamber during surgery, and not the more expensive gels (called OVDs) used in
North America.
Author and "ma'am" at Aurolab |
In 1992, the founders of Aravind Eye Care System built their
own manufacturing facility – a separate business called Aurolab in Madurai,
Tamil Nadu – to make high quality IOLs, sutures, surgical blades, ophthalmic
pharmacologic solutions and OVDs, at much lower per-unit costs than non-Indian
facilities. The cost savings result from
lower labor costs, and economies of scale from high volumes of ophthalmic
products purchased by the Aravind Eye Hospitals. During my one month sojurn in India, I
traveled to Madurai to tour the modern-day Aurolab. Compared to another California pharmaceutical
facility I had visited, the manufacturing plant at Aurolab is state of the art,
with the requisite airflow and construction requirements deserving of its ISO
& CE marks. This bold undertaking by
the Aravind founders was not easy, but its success further bolstered the
success of the cost-effect eye care model.
.....Continue to "10. A Trip to Meet Awesome Friends"
No comments:
Post a Comment